ADHD Carries Excess Mortality; Medication Link Rests on Three Studies
Analysis Psychiatry / Psychopharmacology Confirmatory Grade: Low
Corrigan L, Heywood L, Stewart GR, et al.
Oct 19, 2026 · Published in: JAMA Network Open
ADHD medications may lower mortality risk, study finds.
Polish Psychiatric Association Guides Metabolic Risk Management in Antipsychotic Users
★ Editor's Pick Guideline Psychiatry / Psychopharmacology Practice-changing Grade: Moderate
Wichniak A, Klupa T, Kuryłowicz A, et al.
Oct 10, 2026 · Published in: Psychiatria Polska
Also in Endocrinology / Obesity
Prevent metabolic disorders in patients on antipsychotics with early screening and metformin.
Montelukast Linked to Higher ADHD and Conduct Risk Versus Inhaled Steroids
Analysis Pediatric Pharmacy Confirmatory Grade: Low
Jiao XF, Ducharme FM, Leal LF, et al.
Oct 2, 2026 · Published in: BMC Medicine
Also in Psychiatry / Psychopharmacology
Montelukast may increase neuropsychiatric risks in children with asthma.
Psilocybin in Depression: Mechanistic Breadth, Clinical Promise, Weak Certainty
★ Editor's Pick Analysis Psychiatry / Psychopharmacology Hypothesis-generating Grade: Low
Zhang X, Zhang X, Zhang H, et al.
Sep 26, 2026 · Published in: International Journal of Molecular Sciences
Psilocybin rapidly alleviates treatment-resistant depression symptoms.
Only One in Five Young Adults Adhere After First Psychosis
Analysis Psychiatry / Psychopharmacology Confirmatory Grade: Low
Chi E, Sridhar S, Montesano V, et al.
Sep 24, 2026 · Published in: JAMA Network Open
First-episode psychosis patients show alarmingly low antipsychotic adherence.
Xanomeline-Trospium: A Muscarinic Alternative to Dopamine Blockade
Analysis Psychiatry / Psychopharmacology Confirmatory Grade: Moderate
Avila S, Chen IL
Sep 12, 2026 · Published in: Clinical and Translational Science
Cobenfy offers a novel way to treat schizophrenia with fewer side effects.
LAIAs help intellectual disability patients with SMI, not off-label behavior
Analysis Geriatrics / Geriatric Pharmacy Hypothesis-generating Grade: Low
Leung SM, Lee KJ, Wei Y, et al.
Sep 8, 2026 · Published in: BMJ Mental Health
Also in Psychiatry / Psychopharmacology
LAIAs show promise for PWID with schizophrenia or bipolar disorder, but caution is needed for others.
Neurosteroids reshape postpartum depression care: brexanolone to zuranolone
Analysis Psychiatry / Psychopharmacology Confirmatory Grade: Low
Radonjić NV, Moon KC, Deligiannidis KM
Sep 3, 2026 · Published in: Journal of Neuroendocrinology
Also in Women's Health / Reproductive
Brexanolone and zuranolone redefine postpartum depression treatment with rapid action.
Non-Psychotropic Polypharmacy Rises With Age in Psychiatric Inpatients
Analysis Geriatrics / Geriatric Pharmacy Hypothesis-generating Grade: Low
Uju Y, Kanzaki T, Hosoi R, et al.
Sep 1, 2026 · Published in: Medicine
Also in Psychiatry / Psychopharmacology
Non-psychotropic polypharmacy in psychiatric patients rises with age and comorbidities.
Ketamine for Treatment-Resistant Bipolar Depression: Stratify, Monitor, Maintain
Analysis Psychiatry / Psychopharmacology Hypothesis-generating Grade: Very Low
Lin CC, Wei LC
Aug 31, 2026 · Published in: Bipolar Disorders
Ketamine infusions may offer rapid relief in TRBPD but need tailored maintenance plans.
Oral Ketamine as a Practical, Low-Cost Option for Severe Depression
Analysis Psychiatry / Psychopharmacology Hypothesis-generating Grade: Very Low
Andrade C
Aug 31, 2026 · Published in: The Journal of Clinical Psychiatry
Oral ketamine emerges as a safe, low-cost depression treatment.
Starting Regimen Predicts Early ADHD Treatment Instability in Adults
Analysis Psychiatry / Psychopharmacology Hypothesis-generating Grade: Low
Yonezawa N, Momo K
Aug 19, 2026 · Published in: Biological & Pharmaceutical Bulletin
ADHD treatment choice influences medication stability in Japanese adults.
Half of children with ADHD adhere to prescribed medication
Analysis Psychiatry / Psychopharmacology Confirmatory Grade: Low
Liu J, Kang B, Deng W, et al.
Aug 7, 2026 · Published in: Frontiers in Pharmacology
Also in Pediatrics
Adherence to ADHD medication is only 43.6% in youth.
Psilocybin Feasible for Treatment-Resistant Depression in NHS Setting
Analysis Psychiatry / Psychopharmacology Hypothesis-generating Grade: Low
Rucker JJ, Mantingh T, Kerr-Gaffney J, et al.
Aug 7, 2026 · Published in: Nature Medicine
Psilocybin shows promise for treatment-resistant major depression.
Esketamine Reduces Depression in At-Risk Adolescents
Analysis Psychiatry / Psychopharmacology
Kosik-Gonzalez C, Fu DJ, Chen LN, et al.
Aug 1, 2026 · Published in: Focus (American Psychiatric Publishing)
Esketamine shows promise in quickly reducing severe depression in high-risk adolescents.